Doina Secu

Doina Secu

Auto-generated profile, based on publicly available information

Doina Secu

Laboratory of Human Molecular Genetics, Institute of Mother and Child, Chisinau, Republic of Moldova

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in The Moldovan Medical Journal
Verified
Journal Article
Closed access
DBDaniela Blanita
Daniela Blanita
CBChiril Boiciuc
Chiril Boiciuc
DTDoina Turcan
Doina Turcan
VSVictoria Sacara
Victoria Sacara
NUNatalia Usurelu
Natalia Usurelu
Background: Congenital Disorders of Glycosylation (CDG) are a group of inherited metabolic disorders caused by the defect in various steps in the biosynthesis of glycoproteins and other glycoconjugates. Material and methods: 40 patients under clinical suspicions for CDG at the Institute of Mother and Child were examined by isoelectric focusing of transferrin (IEFT) in collaboration with RadboudUMC, Netherlands and U.S.A. The spectrum of clinical presentations of these patients was multisystem damage, predominantly neurological manifestations. Results: Most of the patients (55%) had early neurological manifestations from the birth, such as hypotonia, psychomotor disability, cerebral MRI abnormalities, seizures (25%), cutis laxa (17.5%), total alopecia (2.5%), abnormal fat pads (2.5%), myopia (7.5%), nystagmus (5%), strabismus (2.5%), stroke-like episodes (2.5.%), ataxia (7.5%), abnormal coagulation (10%), hepatomegaly (35%) and liver cirrhosis (2.5%). Serum samples analyzed by IEFT showed the results: 37 normal, 2 questionable and 1 abnormal patterns. Two samples questionable belongs to the patients with Galactosemia and Fructosemia, which give the false-positive results. The last positive sample is performed additionally for glycomics profiling. In some cases, with IEFT negative profile was performed genetic test and were diagnosed other diseases, mimicking CDG, such as: NARP syndrome, late diagnosed PKU, GSD, Manosidoses, Prader-Willi Syndrome and chromosomal aberrations. Conclusions: The CDG is a rare metabolic disease with multisystem impairment and variety of symptoms which determine overlapping of phenotype with other genetic disorders. The process of diagnosis is very complex and can take several years.

30 October 2026 in Folia Medica
Verified
Journal Article
Open access
PDF file
DSDoina Secu
Doina Secu
DBDaniela Blanita
Daniela Blanita
NUNatalia Usurelu
Natalia Usurelu
CDCalin Deleanu
Calin Deleanu
ANAlina Nicolescu
Alina Nicolescu
VSVictoria Sacara
Victoria Sacara
Introduction : Mitochondrial diseases (MDs) are a heterogeneous group of genetic disorders affecting oxidative phosphorylation, characterized by diverse neuromuscular and multisystemic manifestations, whose clinical variability and genetic complexity necessitate a comprehensive, multidisciplinary diagnostic approach. Aim : This study aims to explore the phenotypic and genotypic spectrum of patients with suspected MD, focusing on mitochondrial genome variations to improve diagnostic accuracy and support genetic counseling. Materials and methods : We analyzed 240 patients with a Nijmegen mitochondrial disease score (NMDS) ≥3, with 90 individuals undergoing comprehensive clinical, biochemical, neuroimaging, and genetic assessments. Descriptive statistics were applied to summarize clinical and biochemical data, while inferential analyses, including chi-square tests and regression models, were employed to explore genotype-phenotype associations. Results : The study delineated a multifaceted clinical spectrum, with neuromuscular dysfunction as the predominant hallmark, evidenced by a high prevalence of developmental delay (88.9%), hypotonia (77.8%), and exercise intolerance (63.3%). Patients with mitochondrial involvement displayed a significantly greater burden of neurological (seizures: 71.9% vs. 43.1%, p =0.009) and cardiac abnormalities (37.5% vs. 15.5%, p =0.018), underscoring their diagnostic relevance. Genetic analysis identified gene variants associated with the patients’ phenotypes in 35.6% of cases, with Complex I being the most frequently affected, emphasizing its pivotal role in mitochondrial dysfunction and disease severity. Conclusion : Our findings highlight the genetic and clinical heterogeneity of MDs, emphasizing the importance of integrating molecular, biochemical, and neuroimaging data to enhance early diagnosis and facilitate personalized treatment strategies.

1 September 2025
Verified
Conference Paper
Closed access
PDF file
DSDoina Secu
Doina Secu
DBDaniela Blanita
Daniela Blanita
NUNatalia Usurelu
Natalia Usurelu
VSVictoria Sacara
Victoria Sacara
Mitochondrial diseases (MDs) are clinically heterogeneous disorders caused by mutations in either mitochondrial DNA (mtDNA) or nuclear genes that impair oxidative phosphorylation. This study aimed to comprehensively characterize the clinical, biochemical, imaging, and molecular features of 37 patients exhibiting mitochondrial involvement, selected from a larger group of 240 individuals with suspected MD based on a Nijmegen Mitochondrial Disease Score ≥3. All patients underwent a standardized evaluation protocol comprising clinical assessment, targeted biochemical and instrumental investigations, qPCR-HRM screening for common mtDNA mutations, and mtDNA sequencing, with additional nuclear gene analysis performed in selected cases. Multisystemic involvement was prevalent, with neuromuscular and central nervous system manifestations being the most frequent. Elevated lactate levels and abnormal neuroimaging findings further supported the clinical diagnosis. Molecular analyses revealed both common and rare mtDNA variants, while nuclear gene defects were identified in a subset of patients, underscoring the genetic complexity of MDs. The integrated approach enabled accurate diagnosis and highlighted the value of combining clinical and molecular data in MD evaluation.

1 September 2025
Verified
Conference Paper
Closed access
PDF file
ICIulia Coliban
Iulia Coliban
NUNatalia Usurelu
Natalia Usurelu
VSVictoria Sacara
Victoria Sacara
Spinal muscular atrophy (SMA) is a severe neuromuscular disorder caused mainly by homozygous deletion of exon 7 in the SMN1 gene. Early qualitative and quantitative diagnosis, especially in the presymptomatic stage, is essential for timely access to treatment and improved outcomes. This study focused on developing and implementing a sensitive, rapid, and costeffective real-time PCR-based method for detecting the exon 7 deletion in SMN1. The test was first validated using 25 clinical samples, then applied in a pilot study on 300 dried blood spot samples to assess its use in presymptomatic newborn screening. The method demonstrated high sensitivity and specificity, a fast turnaround time, and suitability for both symptomatic and presymptomatic diagnosis. Compared to commercial alternatives, the custom assay proved more cost-efficient while maintaining diagnostic reliability. Despite challenges such as lack of national protocols, ethical considerations, and logistical constraints, the findings support integrating this method into routine diagnostics. Its implementation highlights the need for structured policies and infrastructure to enable equitable access to genetic screening for rare diseases like SMA.

28 June 2026 in Acta Medica
Verified
Journal Article
Open access
PDF file
DSDoina Secu
Doina Secu
DBDaniela Blanita
Daniela Blanita
NUNatalia Usurelu
Natalia Usurelu
VSVictoria Sacara
Victoria Sacara
Objectives: This study delineates the diagnostic architecture of patients referred with suspected mitochondrial disease through the integrated analysis of clinical, biochemical, instrumental, and genetic data. By comparing patients with mitochondrial involvement, alternative genetic disorders, and unresolved cases, we aim to define phenotypic and molecular patterns associated with diagnostic stratification and characterize the diverse spectrum of genetic and non-genetic conditions that converge phenotypically on mitochondrial disease. Materials and Methods: A total of 240 patients with clinical suspicion of mitochondrial disease were consecutively enrolled and assessed using a modified Nijmegen Mitochondrial Disease Score. All participants underwent comprehensive clinical, metabolic, instrumental, and neuroimaging evaluations, complemented by systematic molecular analyses, starting with common mitochondrial variant screening and progressing to more extensive targeted investigations guided by clinical and biochemical findings. Comparative analyses across the three groups employed nonparametric and categorical statistical tests. Results: Relevant molecular findings were identified in 81 patients (33.7%), encompassing 37 (15.4%) with mitochondrial involvement and 44 (18.3%) with alternative genetic disorders, while 159 individuals (66.3%) remained unresolved. The mitochondrial group exhibited significantly higher rates of neuromuscular, brainstem, ophthalmic, and cardiac involvement, along with developmental regression, whereas seizures were a shared hallmark of both mitochondrial and non-mitochondrial subgroups. Biochemically, elevated serum lactate and plasma alanine were the most discriminative markers for the mitochondrial group, with a significantly higher prevalence of abnormal acylcarnitine profiles and organic aciduria in both the mitochondrial and alternative genetic subgroups. The undiagnosed cohort demonstrated phenotypic convergence with confirmed cases but lacked definitive molecular correlates despite extensive evaluation. Conclusions: These findings underscore the intrinsic complexity and phenotypic heterogeneity of suspected mitochondrial disease, affirming the critical role of integrated clinical, metabolic, instrumental, and molecular assessment while simultaneously highlighting the limitations of current diagnostic paradigms and the imperative for expanded genomic and functional strategies to enhance resolution in unresolved cases.

1 September 2026 in Moldovan Journal of Health Sciences
Verified
Journal Article
Open access
PDF file
DSDoina Secu
Doina Secu
DBDaniela Blanita
Daniela Blanita
NUNatalia Usurelu
Natalia Usurelu
VSVictoria Sacara
Victoria Sacara
ANAlina Nicolescu
Alina Nicolescu
CDCalin Deleanu
Calin Deleanu
Introduction. Mitochondrial diseases present heterogeneous clinical features that overlap with numerous genetic disorders, making early diagnostic stratification essential. This study aimed to evaluate the performance of a stepwise molecular diagnostic algorithm integrating High-Resolution Melting qPCR screening and targeted sequencing in individuals suspected of mitochondrial pathology based on a Nijmegen Mitochondrial Disease Score (NMDS) ≥3. Materials and methods. The analysis included 240 patients with clinical suspicion of mitochondrial disease and an NMDS ≥3, all evaluated through a standardized clinical, biochemical, and instrumental assessment. Molecular testing followed a tiered workflow: initial qPCR-HRM screening for seven common mtDNA mutations, followed by targeted Sanger sequencing of mitochondrial genes, including POLG hotspot regions, in patients meeting predefined clinical and NMDS thresholds. For individuals subsequently identified with non-mitochondrial etiologies, next-generation sequencing approaches were performed in accredited external laboratories. Statistical evaluation relied on descriptive statistical methods and non-parametric comparative analyses. Results. Molecular analysis confirmed mitochondrial involvement in 37 patients (15.4%) and identified non-mitochondrial genetic disorders in 44 patients (18.3%), while 159 individuals (66.3%) remained without a definitive molecular diagnosis. Patients with mitochondrial involvement showed higher frequencies of severe neuromuscular dysfunction, developmental regression, ophthalmic manifestations including ophthalmoplegia, and cardiovascular involvement. By contrast, neurodevelopmental and behavioral impairments and dysmorphic features were more prevalent in non-mitochondrial and undiagnosed patients. Biochemically, elevated plasma lactate and hyperalaninemia were significantly more common among individuals with mitochondrial involvement. Neuroimaging findings in this group were characterized by cerebral and cerebellar atrophy and basal ganglia abnormalities. Consistently, NMDS values were markedly higher in patients with mitochondrial involvement, and their integration as threshold-based decision points within the stepwise diagnostic algorithm substantially enhanced diagnostic stratification, enabling more precise differentiation between mitochondrial involvement and alternative genetic etiologies. Conclusions. The structured algorithm integrating NMDS-based selection, qPCR-HRM screening, and targeted sequencing demonstrated effective stratification of patients with suspected mitochondrial disease, achieving a combined diagnostic rate of 33.7%. These findings support the utility of this tiered approach in distinguishing mitochondrial from non-mitochondrial genetic conditions and in optimizing molecular diagnostic workflows.